3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.

@article{McEvoy198934DiaminopyridineIT,
  title={3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.},
  author={Kathleen M McEvoy and Anthony J Windebank and Jasper R. Daube and Phillip A. Low},
  journal={The New England journal of medicine},
  year={1989},
  volume={321 23},
  pages={1567-71}
}
Lambert-Eaton myasthenic syndrome is characterized by muscle weakness, hyporeflexia, and autonomic dysfunction, which result from impaired release of acetylcholine from cholinergic nerve terminals. It is frequently associated with cancer, it is autoimmune-mediated, and treatment has been unsatisfactory. 3,4-Diaminopyridine enhances the release of acetylcholine. In this prospective, double-blind, placebo-controlled crossover study of 12 patients with Lambert-Eaton myasthenic syndrome (7 of whom… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 62 extracted citations

Similar Papers

Loading similar papers…